Nierenberg, Andrew
Lavin, Philip
Javitt, Daniel C.
Shelton, Richard
Sapko, Michael T.
Mathew, Sanjay
Besthof, Robert E.
Javitt, Jonathan C.
Funding for this research was provided by:
NRx Pharmaceuticals, Inc
Article History
Received: 4 May 2023
Accepted: 20 July 2023
First Online: 13 August 2023
Declarations
:
: The study was conducted in accordance with the ethical principles as set out in the Declaration of Helsinki and its amendments and in compliance with the approved protocol of the United States Food and Drug Administration (FDA). The protocol (NCT02974010) and its associated Informed Consent Agreement were reviewed and approved by the central Institutional Review Board (IRB) of this study, Schulman IRB (now Advarra, Inc). Participants were evaluated to ensure that they were capable of understanding the nature of this study and its potential risks, discomforts, and benefits. All participants provided written informed consent.
: Not applicable.
: DCJ, JCJ, RAB receive compensation from and have equity interest in NRx Pharmaceuticals, Inc. MTS receives compensation from NRx Pharmaceuticals, Inc. Lavin Statistical Associates is paid for independent statistical analysis by NRx Pharmaceuticals, Inc.